Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Growth Hormone Deficiency
Interventions
Recombinant Human Growth Hormone, Recombinant Human IGF-1
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 65 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Cystic Fibrosis
Interventions
Human recombinant growth hormone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Conditions
Growth Hormone Deficiency, Dwarfism
Interventions
Dextromethorphan and Caffeine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
4 Years to 14 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more
Completed Phase 2Phase 3 Interventional Results available

Assessment of Mechanisms of Improved Wound Healing

NCT00673309
Conditions
Burns
Interventions
Stable Isotope Infusion study, Insulin High Dose, oxandrolone, Propranolol, Growth Hormone, Insulin Low Dose, IGF-1/IGFBP-3, Itraconazole, Growth Hormone and Propranolol, Oxandrolone and Propranolol, Placebo or Control
Procedure · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Noonan Syndrome
Interventions
Vosoritide Injection
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
3 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2041
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 20 more
Conditions
End Stage Renal Disease
Interventions
nutritional supplement, recombinant human growth hormone (rcGH), exercise
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Phase 2Phase 3 Interventional Results available

Long-Term Treatment With rhIGF-1 in GHIS

NCT00571727
Conditions
Growth Hormone Insensitivity Syndrome
Interventions
mecasermin
Drug
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 21 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2011
U.S. locations
1
States / cities
Brisbane, California
Conditions
Phelan McDermid Syndrome
Interventions
Recombinant human Growth hormone
Drug
Lead sponsor
Swathi Sethuram
Other
Eligibility
2 Years to 12 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Adult Growth Hormone Deficiency
Interventions
ALTU-238
Drug
Lead sponsor
Altus Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Louisville, Kentucky • Galveston, Texas • San Antonio, Texas
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
Conditions
Healthy Volunteers
Interventions
Norditropin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
25 Years to 50 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Letrozole, Questionnaire Administration, Tamoxifen Citrate
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
521
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more
Conditions
Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
Interventions
Recombinant human growth hormone; pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Traumatic Brain Injury
Interventions
Growth Hormone, Sildenafil, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Osteoarthritis, Knee
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
John Sledge
Other
Eligibility
18 Years to 72 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Kidney Failure, Chronic
Interventions
growth hormone
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
asparaginase, daunorubicin hydrochloride, fludarabine phosphate, therapeutic hydrocortisone, allogeneic bone marrow transplantation, 3-dimensional conformal radiation therapy, filgrastim, cytarabine, idarubicin, dexamethasone, thioguanine, etoposide, methotrexate, cyclophosphamide, aldesleukin, busulfan
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Arcadia, California
Conditions
Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Interventions
Serostim
Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Beach, California + 18 more
Conditions
Growth Hormone Deficiency, Traumatic Brain Injury
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Conditions
Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 18 Years
Enrollment
22,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Plainsboro, New Jersey
Conditions
Adult Growth Hormone Deficiency
Interventions
somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
23 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Escondido, California • Laguna Hills, California • Los Angeles, California + 5 more
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Recombinant human growth hormone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
23 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Portland, Oregon